

Naoki Niikura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/829228/publications.pdf>

Version: 2024-02-01

41
papers

1,420
citations

430442

18
h-index

329751

37
g-index

41
all docs

41
docs citations

41
times ranked

2489
citing authors

#	ARTICLE	IF	CITATIONS
1	Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors. <i>Journal of Clinical Oncology</i> , 2012, 30, 593-599.	0.8	361
2	Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 103-112.	1.1	141
3	Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. <i>Cancer Science</i> , 2016, 107, 1730-1735.	1.7	125
4	Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer. <i>Oncotarget</i> , 2017, 8, 103671-103681.	0.8	76
5	FDG-PET/CT Compared with Conventional Imaging in the Detection of Distant Metastases of Primary Breast Cancer. <i>Oncologist</i> , 2011, 16, 1111-1119.	1.9	73
6	Treatment Outcome and Prognostic Factors for Patients with Bone-Only Metastases of Breast Cancer: A Single-Institution Retrospective Analysis. <i>Oncologist</i> , 2011, 16, 155-164.	1.9	59
7	Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. <i>European Journal of Cancer</i> , 2019, 118, 41-48.	1.3	48
8	Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2946-2956.	0.8	46
9	Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer. <i>Cancer Science</i> , 2012, 103, 1508-1512.	1.7	40
10	Prognostic Significance of the Ki67 Scoring Categories in Breast Cancer Subgroups. <i>Clinical Breast Cancer</i> , 2014, 14, 323-329.e3.	1.1	34
11	Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples. <i>Scientific Reports</i> , 2019, 9, 13343.	1.6	33
12	The impact of COVID-19 on surgical procedures in Japan: analysis of data from the National Clinical Database. <i>Surgery Today</i> , 2022, 52, 22-35.	0.7	33
13	Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 277-284.	1.1	32
14	Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 39-47.	1.1	28
15	Brain Metastases in Breast Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 1133-1140.	0.6	26
16	Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 523-531.	1.1	25
17	Latest biopsy approach for suspected metastases in patients with breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 711-719.	12.5	22
18	Assessment of the Ki67 labeling index: a Japanese validation ring study. <i>Breast Cancer</i> , 2016, 23, 92-100.	1.3	20

#	ARTICLE	IF	CITATIONS
19	Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases. <i>Cancer</i> , 2012, 118, 2039-2047.	2.0	19
20	Initial Staging Impact of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Locally Advanced Breast Cancer. <i>Oncologist</i> , 2011, 16, 772-782.	1.9	16
21	Reverse-Phase Protein Array for Prediction of Patients at Low Risk of Developing Bone Metastasis From Breast Cancer. <i>Oncologist</i> , 2014, 19, 909-914.	1.9	15
22	Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 81-87.	1.1	15
23	Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101. <i>Breast</i> , 2019, 47, 1-9.	0.9	13
24	Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study. <i>Breast Cancer</i> , 2021, 28, 896-903.	1.3	11
25	Evaluation of oral care to prevent oral mucositis in estrogen receptor-positive metastatic breast cancer patients treated with everolimus (Oral Care-BC): randomized controlled phase III trial. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 879-882.	0.6	10
26	Comprehensive prognostic report of the Japanese Breast Cancer Society registry in 2006. <i>Breast Cancer</i> , 2016, 23, 62-72.	1.3	10
27	Diagnostic performance of 18F-fluorodeoxyglucose PET/CT and bone scintigraphy in breast cancer patients with suspected bone metastasis. <i>Breast Cancer</i> , 2016, 23, 662-667.	1.3	10
28	Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor-Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care-BC): A Randomized Controlled Phase III Trial. <i>Oncologist</i> , 2020, 25, e223-e230.	1.9	10
29	Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 95-100.e1.	1.1	9
30	Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status. <i>Journal of Cancer</i> , 2017, 8, 1045-1052.	1.2	9
31	Breast conserving surgery for male noninvasive intracystic papillary carcinoma: a case report. <i>Tokai Journal of Experimental and Clinical Medicine</i> , 2010, 35, 13-6.	0.4	9
32	The Role of ¹⁸ F-FDG-Positron Emission Tomography/Computed Tomography in Staging Primary Breast Cancer. <i>Journal of Cancer</i> , 2010, 1, 51-53.	1.2	8
33	Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: a comparative registry-based study. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 585-596.	1.1	8
34	Diagnosis of oligometastasis. <i>Translational Cancer Research</i> , 2020, 9, 5032-5037.	0.4	6
35	Immunological profiles of the breast cancer microenvironment represented by tumor-infiltrating lymphocytes and PD-L1 expression. <i>Scientific Reports</i> , 2022, 12, 8098.	1.6	6
36	Comparison of Ki-67 labeling index measurements using digital image analysis and scoring by pathologists. <i>Breast Cancer</i> , 2018, 25, 768-777.	1.3	3

#	ARTICLE	IF	CITATIONS
37	Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC. <i>BMC Cancer</i> , 2021, 21, 34.	1.1	3
38	Oral care and oral assessment guide in breast cancer patients receiving everolimus and exemestane: subanalysis of a randomized controlled trial (Oral Care-BC). <i>Annals of Translational Medicine</i> , 2021, 9, 535-535.	0.7	3
39	Comparative Study of the One-step Nucleic Acid Amplification Assay and Conventional Histological Examination for the Detection of Breast Cancer Sentinel Lymph Node Metastases. <i>Tokai Journal of Experimental and Clinical Medicine</i> , 2014, 39, 122-7.	0.4	3
40	Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment. <i>Breast Cancer</i> , 2013, 20, 67-74.	1.3	2
41	Stability of HER2 Status by Dual-color in Situ Hybridization Before and After Neoadjuvant Chemotherapy in Breast Cancer. <i>Tokai Journal of Experimental and Clinical Medicine</i> , 2020, 45, 176-181.	0.4	0